{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:44:07Z","timestamp":1770684247539,"version":"3.49.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,10,4]],"date-time":"2013-10-04T00:00:00Z","timestamp":1380844800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Artif Organs"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1007\/s10047-013-0733-1","type":"journal-article","created":{"date-parts":[[2013,10,3]],"date-time":"2013-10-03T07:49:10Z","timestamp":1380786550000},"page":"110-113","source":"Crossref","is-referenced-by-count":13,"title":["Effects of blood purification therapy on a patient with ifosfamide-induced neurotoxicity and acute kidney injury"],"prefix":"10.1007","volume":"17","author":[{"given":"Hiroaki","family":"Nishimura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Enokida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Nagano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Yokouchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Hayami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Setsuro","family":"Komiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,10,4]]},"reference":[{"key":"733_CR1","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1200\/JCO.20.2.426","volume":"20","author":"AM Goorin","year":"2002","unstructured":"Goorin AM, Harris MB, Bernstein M, Ferguson W, Devidas M, Siegal GP, Gebhardt MC, Schwartz CL, Link M, Grier HE. Phase ii\/iii trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. J Clin Oncol. 2002;20:426\u201333.","journal-title":"J Clin Oncol"},{"key":"733_CR2","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s00776-009-1431-y","volume":"15","author":"T Tajino","year":"2010","unstructured":"Tajino T, Kikuchi S, Yamada H, Takeda A, Konno S. Ifosfamide encephalopathy associated with chemotherapy for musculoskeletal sarcomas: incidence, severity, and risk factors. J Orthop Sci. 2010;15:104\u201311.","journal-title":"J Orthop Sci"},{"key":"733_CR3","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/pbc.20228","volume":"44","author":"SG Berrak","year":"2005","unstructured":"Berrak SG, Pearson M, Berberoglu S, Ilhan IE, Jaffe N. High-dose ifosfamide in relapsed pediatric osteosarcoma: therapeutic effects and renal toxicity. Pediatr Blood Cancer. 2005;44:215\u20139.","journal-title":"Pediatr Blood Cancer"},{"key":"733_CR4","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1093\/ndt\/16.5.1088","volume":"16","author":"R Fiedler","year":"2001","unstructured":"Fiedler R, Baumann F, Deschler B, Osten B. Haemoperfusion combined with haemodialysis in ifosfamide intoxication. Nephrol Dial Transpl. 2001;16:1088\u20139.","journal-title":"Nephrol Dial Transpl"},{"key":"733_CR5","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1124\/dmd.106.014043","volume":"35","author":"SK Bruggemann","year":"2007","unstructured":"Bruggemann SK, Pfaffle S, Peters SO, Wagner T. Influence of short-term use of dexamethasone on the pharmacokinetics of ifosfamide in patients. Drug Metab Dispos. 2007;35:1721\u20134.","journal-title":"Drug Metab Dispos"},{"key":"733_CR6","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0140-6736(86)92227-0","volume":"2","author":"MP Goren","year":"1986","unstructured":"Goren MP, Wright RK, Pratt CB, Pell FE. Dechloroethylation of ifosfamide and neurotoxicity. Lancet. 1986;2:1219\u201320.","journal-title":"Lancet"},{"key":"733_CR7","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s002800050720","volume":"41","author":"L Carlson","year":"1998","unstructured":"Carlson L, Goren MP, Bush DA, Griener JC, Quigley R, Tkaczewski I, Kamen BA, Weitman SD. Toxicity, pharmacokinetics, and in vitro hemodialysis clearance of ifosfamide and metabolites in an anephric pediatric patient with Wilms\u02bc tumor. Cancer Chemother Pharmacol. 1998;41:140\u20136.","journal-title":"Cancer Chemother Pharmacol"},{"key":"733_CR8","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1054\/bjoc.1999.0917","volume":"82","author":"J Pelgrims","year":"2000","unstructured":"Pelgrims J, De Vos F, Van den Brande J, Schrijvers D, Prove A, Vermorken JB. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer. 2000;82:291\u20134.","journal-title":"Br J Cancer"},{"key":"733_CR9","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1046\/j.1442-2042.1999.06130.x","volume":"6","author":"S Hoshi","year":"1999","unstructured":"Hoshi S, Itoh A, Kato S, Suzuki K, Kawamura S, Orikasa S. Severe rhabdomyolysis as a complication of high-dose chemotherapy in a patient with advanced testicular cancer. Int J Urol. 1999;6:56\u20137.","journal-title":"Int J Urol"},{"key":"733_CR10","first-page":"375","volume":"58","author":"RA DeFronzo","year":"1974","unstructured":"DeFronzo RA, Abeloff M, Braine H, Humphrey RL, Davis PJ. Renal dysfunction after treatment with isophosphamide (nsc-109724). Cancer Chemother Rep. 1974;58:375\u201382.","journal-title":"Cancer Chemother Rep"},{"key":"733_CR11","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1136\/adc.65.7.732","volume":"65","author":"R Skinner","year":"1990","unstructured":"Skinner R, Pearson AD, Price L, Coulthard MG, Craft AW. Nephrotoxicity after ifosfamide. Arch Dis Child. 1990;65:732\u20138.","journal-title":"Arch Dis Child"},{"key":"733_CR12","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/(SICI)1096-911X(199601)26:1<36::AID-MPO5>3.0.CO;2-W","volume":"26","author":"C Canpolat","year":"1996","unstructured":"Canpolat C, Pearson P, Robertson R, Jaffe N. Ifosfamide tolerance in osteosarcoma patients previously treated with cis-diamminedichloroplatinum-ii: renal, hematologic, and neurologic observations. Med Pediatr Oncol. 1996;26:36\u201347.","journal-title":"Med Pediatr Oncol"},{"key":"733_CR13","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1002\/1097-0142(19940515)73:10<2506::AID-CNCR2820731009>3.0.CO;2-S","volume":"73","author":"G Rosen","year":"1994","unstructured":"Rosen G, Forscher C, Lowenbraun S, Eilber F, Eckardt J, Holmes C, Fu YS. Synovial sarcoma. Uniform response of metastases to high dose ifosfamide. Cancer. 1994;73:2506\u201311.","journal-title":"Cancer"},{"key":"733_CR14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/BF00865466","volume":"8","author":"M Mohrmann","year":"1994","unstructured":"Mohrmann M, Ansorge S, Schmich U, Schonfeld B, Brandis M. Toxicity of ifosfamide, cyclophosphamide and their metabolites in renal tubular cells in culture. Pediatr Nephrol. 1994;8:157\u201363.","journal-title":"Pediatr Nephrol"},{"key":"733_CR15","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1002\/1097-0142(19930301)71:5<1898::AID-CNCR2820710529>3.0.CO;2-Q","volume":"71","author":"FH Kung","year":"1993","unstructured":"Kung FH, Pratt CB, Vega RA, Jaffe N, Strother D, Schwenn M, Nitschke R, Homans AC, Holbrook CT, Golembe B, Bernstein M, Krischer JP. Ifosfamide\/etoposide combination in the treatment of recurrent malignant solid tumors of childhood. A pediatric oncology group phase ii study. Cancer. 1993;71:1898\u2013903.","journal-title":"Cancer"},{"key":"733_CR16","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1200\/JCO.1987.5.8.1191","volume":"5","author":"JS Miser","year":"1987","unstructured":"Miser JS, Kinsella TJ, Triche TJ, Tsokos M, Jarosinski P, Forquer R, Wesley R, Magrath I. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol. 1987;5:1191\u20138.","journal-title":"J Clin Oncol"},{"key":"733_CR17","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.ejca.2006.10.023","volume":"43","author":"MC Deley Le","year":"2007","unstructured":"Le Deley MC, Guinebretiere JM, Gentet JC, Pacquement H, Pichon F, Marec-Berard P, Entz-Werle N, Schmitt C, Brugieres L, Vanel D, Dupouy N, Tabone MD, Kalifa C. Sfop os94. A randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. Eur J Cancer. 2007;43:752\u201361.","journal-title":"Eur J Cancer"},{"key":"733_CR18","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1200\/JCO.1991.9.8.1495","volume":"9","author":"CB Pratt","year":"1991","unstructured":"Pratt CB, Meyer WH, Jenkins JJ, Avery L, McKay CP, Wyatt RJ, Hancock ML. Ifosfamide, Fanconi\u02bcs syndrome, and rickets. J Clin Oncol. 1991;9:1495\u20139.","journal-title":"J Clin Oncol"},{"key":"733_CR19","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1200\/JCO.1991.9.12.2177","volume":"9","author":"A Suarez","year":"1991","unstructured":"Suarez A, McDowell H, Niaudet P, Comoy E, Flamant F. Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: an International Society of Pediatric Oncology report. J Clin Oncol. 1991;9:2177\u201382.","journal-title":"J Clin Oncol"},{"key":"733_CR20","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1200\/JCO.1994.12.1.159","volume":"12","author":"R Rossi","year":"1994","unstructured":"Rossi R, Godde A, Kleinebrand A, Riepenhausen M, Boos J, Ritter J, Jurgens H. Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients. J Clin Oncol. 1994;12:159\u201365.","journal-title":"J Clin Oncol"},{"key":"733_CR21","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1200\/JCO.1989.7.1.126","volume":"7","author":"KH Antman","year":"1989","unstructured":"Antman KH, Ryan L, Elias A, Sherman D, Grier HE. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol. 1989;7:126\u201331.","journal-title":"J Clin Oncol"}],"container-title":["Journal of Artificial Organs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10047-013-0733-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10047-013-0733-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10047-013-0733-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,28]],"date-time":"2019-07-28T15:53:01Z","timestamp":1564329181000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10047-013-0733-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,4]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["733"],"URL":"https:\/\/doi.org\/10.1007\/s10047-013-0733-1","relation":{},"ISSN":["1434-7229","1619-0904"],"issn-type":[{"value":"1434-7229","type":"print"},{"value":"1619-0904","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,4]]}}}